Skip to main content
. 2022 Jun 28;12(6):e061610. doi: 10.1136/bmjopen-2022-061610

Table 4.

Showing the details of treatment received

Treatment* First wave (n=1039)
n (%)
Second wave (n=991)
n (%)
P value†
Dexamethasone 178 (17.1) 473 (47.7) <0.001
Anticoagulation 1012 (97.4) 981 (99) 0.007
Favipiravir 230 (22.1) 704 (71) <0.001
Hydroxychloroquine 920 (88.5) 598 (60.3) <0.001
Lopinavir/ritonavir 369 (35.5) 630 (63.6) <0.001
Anakinra 28 (2.7) 105 (10.6) <0.001
Tocilizumab 21 (2.0) 19 (1.9) 0.866
Amoxicillin/clavulanic acid 633 (60.9) 290 (29.3) <0.001
Ceftriaxone/cefuroxime 772 (74.3) 699 (70.5) 0.058
Azithromycin/clarithromycin 770 (74.1) 415 (41.9) <0.001
Piperacillin/tazobactum 51 (4.9) 68 (6.9) 0.061

In all statistical comparative analysis performed, second wave was considered as a reference group.

*Some patients might have received more than one type of treatments.

†Pearson χ2 test.